NysnoBio has started manufacturing their first product at Thermo Fisher Scientific's giant new plant in the Boston metro area.

San Francisco | July 17, 2023 – NysnoBio is pleased to announce additional funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance their Parkin gene therapy development candidate NB001 towards IND status. This funding will support NB001 product manufacturing to enable the IND safety studies in preparation for human clinical trials.

NysnoBio Collaborator and MJFF grant Co-PI David Eidelberg recently published a review of his 20+-year journey toward creating an imaging modality that has the potential to transform diagnosis and treatment of patients with neurodegenerative conditions like …

NysnoBio is developing a gene therapy to slow progression in people under age 50…

NysnoBio partner, Rune Labs, has secured FDA clearance for Parkinson's Disease (PD) monitoring through its StrivePD ecosystem on the Apple Watch, a line of smartwatches produced by Apple, Inc. With this clearance…

Mutations in the genes encoding Parkin/PRKN and PTEN-induced kinase 1 (PINK1) cause selective degeneration of the midbrain dopaminergic neurons in autosomal recessive juvenile parkinsonism (1,2).

NysnoBio announces funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) for the study Neural Network Imaging Analysis in Parkin-PD Patients. Drs. Jennifer Johnston (Nysnobio), David Eidelberg, and Genko Oyama, will combine their talents and expertise on this new

In a webinar brought to you by Bio-Techne and The Scientist, Dr. Jennifer Johnston discusses the past 20 years of her career, and how her basic research into ubiquitin-proteasome system elements—including Parkin E3 ligase—continues to

J. William Langston, who has been studying and treating Parkinson’s disease for nearly 40 years, always has found it striking that so many more men than women show up in his clinic. His observation is not anecdotal.

San Francisco | June 1, 2021 - Together with Aligning Science Against Parkinson’s (ASAP), and the Michael J. Fox Foundation for Parkinson’s Research, NysnoBio and its founder Dr. Jennifer A. Johnston announce the launch of an innovative, multi-year study into the most common genetic causes of Parkinson’s Disease (PD).

The lack of tailored treatments for sufferers of Young Onset Parkinson’s Disease (YOPD) has destroyed countless lives. The good news: recent advances at NysnoBio may point toward a gene-based cure for YOPD, as well as late-Onset Parkinson’s and other challenging CNS disorders.

Dr. Deniz Kirik (Lund University), Dr. Matt Goldberg (University of Alabama at Birmingham), and Dr. Jennifer Johnston (NsynoBio and NysnoBioMetriX) proudly announce continued funding from The Michael J. Fox Foundation (MJFF) for work to benefit the broader Parkinson’s community. This new study

In partnership with Aligning Science Across Parkinson's (ASAP) and The Michael J. Fox Foundation (MJFF), NysnoBio and its non-profit arm NysnoBioMetriX (NBX) are proud to announce the launch of a novel, patient-driven data repository supporting the newly launched ASAP Collaborative Research Network.